Top

Published in:

01-11-2012 | Review

Dendritic cells in Leishmania major infections: mechanisms of parasite uptake, cell activation and evidence for physiological relevance

Authors: Kordula Kautz-Neu, Kirsten Schwonberg, Michael R. Fischer, Anja I. Schermann, Esther von Stebut

Published in: Medical Microbiology and Immunology | Issue 4/2012

Abstract

Leishmaniasis is one of the most important infectious diseases worldwide; a vaccine is still not available. Infected dendritic cells (DC) are critical for the initiation of protective Th1 immunity against Leishmania major. Phagocytosis of L. major by DC leads to cell activation, IL-12 release and (cross-) presentation of Leishmania antigens by DC. Here, we review the role of Fcγ receptor- and B cell-mediated processes for parasite internalization by DC. In addition, the early events after parasite inoculation that consist of mast cell activation, parasite uptake by skin-resident macrophages (MΦ), followed by neutrophil and monocyte immigration and DC activation are described. All these events contribute significantly to antigen processing in infected DC and influence resulting T cell priming in vivo. A detailed understanding of the role of DC for the development of efficient anti-Leishmania immunity will aid the development of potent anti-parasite drugs and/or vaccines.

Herwaldt BL (1999) Leishmaniasis. Lancet 354:1191–1199PubMedCrossRef

Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2:845–858PubMedCrossRef

Bogdan C (2012) Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 71:60–66CrossRef

*von Stebut E (2007) Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17:115–122

Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D (2000) A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 165:969–977PubMed

Peters NC, Sacks DL (2009) The impact of vector-mediated neutrophil recruitment on cutaneous leishmaniasis. Cell Microbiol 11:1290–1296PubMedCrossRef

*von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC (1998) Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 188:1547–1552CrossRef

*von Stebut E, Belkaid Y, Nguyen BV, Cushing M, Sacks DL, Udey MC (2000) Leishmania major-infected murine Langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis. Eur J Immunol 30:3498–3506CrossRef

Misslitz AC, Bonhagen K, Harbecke D, Lippuner C, Kamradt T, Aebischer T (2004) Two waves of antigen-containing dendritic cells in vivo in experimental Leishmania major infection. Eur J Immunol 34:715–725PubMedCrossRef

10.

Baldwin T, Henri S, Curtis J, O’Keeffe M, Vremec D, Shortman K, Handman E (2004) Dendritic cell populations in Leishmania major-infected skin and draining lymph nodes. Infect Immun 72:1991–2001PubMedCrossRef

11.

*von Stebut E (2007) Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermatol 16:340–346CrossRef

12.

*Woelbing F, Kostka SL, Moelle K, Belkaid Y, Sunderkoetter C, Verbeek S, Waisman A, Nigg AP, Knop J, Udey MC, von Stebut E (2006) Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors and facilitates acquisition of protective immunity. J Exp Med 203:177–188PubMedCrossRef

13.

Locksley RM, Fowell DJ, Shinkai K, Wakil AE, Lacy D, Bix M (1998) Development of CD4⁺ effector T cells and susceptibility to infectious diseases. Adv Exp Med Biol 452:45–52PubMedCrossRef

14.

Blank C, Fuchs H, Rappersberger K, Röllinghoff M, Moll H (1993) Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major. J Infect Dis 167:418–425PubMedCrossRef

15.

Flohé SB, Bauer C, Flohé S, Moll H (1998) Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 28:3800–3811PubMedCrossRef

16.

Ahuja SS, Mummidi S, Malech HL, Ahuja SK (1998) Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-γ and IL-12. J Immunol 161:868–876PubMed

17.

*Belkaid Y, von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, Udey MC, Sacks D (2002) CD8⁺ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168:3992–4000PubMed

18.

Schönlau F, Scharffetter-Kochanek K, Grabbe S, Pietz B, Sorg C, Sunderkötter C (2000) In experimental leishmaniasis deficiency of CD18 results in parasite dissemination associated with altered macrophage functions and incomplete Th1 cell response. Eur J Immunol 30:2729–2740PubMedCrossRef

19.

Köhl J (2006) Self, non-self, and danger: a complementary view. Adv Exp Med Biol 586:71–94PubMedCrossRef

20.

Domínguez M, Toraño A (1999) Immune adherence-mediated opsonophagocytosis: the mechanism of Leishmania infection. J Exp Med 189:25–35PubMedCrossRef

21.

*Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E (2009) IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol 182:3039–3046PubMedCrossRef

22.

Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM (2005) A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201:747–754PubMedCrossRef

23.

Editor’s Choice (2006) Primed by parasites. Science 311:579–581

24.

Wanderley JL, Barcinski MA (2010) Apoptosis and apoptotic mimicry: the Leishmania connection. Cell Mol Life Sci 67:1653–1659PubMedCrossRef

25.

Wanderley JL, Moreira ME, Benjamin A, Bonomo AC, Barcinski MA (2006) Mimicry of apoptotic cells by exposing phosphatidylserine participates in the establishment of amastigotes of Leishmania (L) amazonensis in mammalian hosts. J Immunol 176:1834–1839PubMed

26.

*Maurer M, Lopez Kostka S, Siebenhaar F, Moelle K, Metz M, Knop J, von Stebut E (2006) Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J 20:2460–2467PubMedCrossRef

27.

Wershil BK, Theodos CM, Galli SJ, Titus RG (1994) Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse. J Immunol 152:4563–4571PubMed

28.

Bidri M, Vouldoukis I, Mossalayi MD, Debre P, Guillosson JJ, Mazier D, Arock M (1997) Evidence for direct interaction between mast cells and Leishmania parasites. Parasite Immunol 19:475–483PubMedCrossRef

29.

Grimaldi G Jr, Soares MJ, Moriearty PL (1984) Tissue eosinophilia and Leishmania mexicana eosinophil interactions in murine cutaneous leishmaniasis. Parasite Immunol 6:397–408PubMedCrossRef

30.

Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8:1095–1104PubMedCrossRef

31.

*Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer M (2011) Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol 41:1883–1893PubMedCrossRef

32.

Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, Kamhawi S, Lawyer P, Fay MP, Germain RN, Sacks D (2008) In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321:970–974PubMedCrossRef

33.

Laskay T, van Zandbergen G, Solbach W (2008) Neutrophil granulocytes as host cells and transport vehicles for intracellular pathogens: apoptosis as infection-promoting factor. Immunobiology 213:183–191PubMedCrossRef

34.

John B, Hunter CA (2008) Immunology. Neutrophil soldiers or Trojan Horses? Science 321:917–918PubMedCrossRef

35.

Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL (2012) Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-Leishmania response. PLoS Pathog 8:e1002536PubMedCrossRef

36.

*von Stebut E, Metz M, Milon G, Knop J, Maurer M (2003) Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1α/β released from neutrophils recruited by mast cell-derived TNFα. Blood 101:210–215CrossRef

37.

Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ (2006) Mast cell-associated TNF promotes dendritic cell migration. J Immunol 176:4102–4112PubMed

38.

Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC (2004) Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 20:381–392PubMedCrossRef

39.

Jawdat DM, Albert EJ, Rowden G, Haidl ID, Marshall JS (2004) IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol 173:5275–5282PubMed

40.

Mekori YA, Metcalfe DD (1999) Mast cell-T cell interactions. J Allergy Clin Immunol 104:517–523PubMedCrossRef

41.

Nakano N, Nishiyama C, Kanada S, Niwa Y, Shimokawa N, Ushio H, Nishiyama M, Okumura K, Ogawa H (2007) Involvement of mast cells in IL-12/23 p40 production is essential for survival from polymicrobial infections. Blood 109:4846–4855PubMedCrossRef

42.

Mitchell GF (1983) Murine cutaneous leishmaniasis: resistance in reconstituted nude mice and several F1 hybrids infected with Leishmania tropica major. J Immunogenet 10:395–412PubMedCrossRef

43.

Holaday BJ, Sadick MD, Wang Z-E, Reiner SL, Heinzel FP, Parslow TG, Locksley RM (1991) Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like lines. J Immunol 147:1653–1658PubMed

44.

Locksley RM, Reiner SL, Hatam F, Littman DR, Killeen N (1993) Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science 261:1448–1451PubMedCrossRef

45.

Titus RG, Ceredig R, Cerottini JC, Louis JA (1985) Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J Immunol 135:2108–2114PubMed

46.

Titus RG, Milon G, Marchal G, Vassalli P, Cerottini JC, Louis JA (1987) Involvement of specific Lyt-2⁺ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur J Immunol 17:1429–1433PubMedCrossRef

47.

Heinzel FP, Sadick MD, Mutha SS, Locksley RM (1991) Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4⁺ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 88:7011–7015PubMedCrossRef

48.

Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, Waldmann R, Locksley RM, Glaichenhaus N (1995) Expression cloning of a protective Leishmania antigen. Science 268:563–566PubMedCrossRef

49.

Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 169:59–72PubMedCrossRef

50.

Müller I, Kropf P, Louis JA, Milon G (1994) Expansion of gamma interferon-producing CD8⁺ T cells following secondary infection of mice immune to Leishmania major. Infect Immun 62:2575–2581PubMed

51.

Erb K, Blank C, Ritter U, Bluethmann H, Moll H (1996) Leishmania major infection in major histocompatibility complex class II-deficient mice: CD8⁺ T cells do not mediate a protective immune response. Immunobiology 195:243–260PubMedCrossRef

52.

Uzonna JE, Joyce KL, Scott P (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8⁺ T cells. J Exp Med 199:1559–1566PubMedCrossRef

53.

*Kronenberg K, Brosch S, Butsch F, Tada Y, Shibagaki N, Udey MC, von Stebut E (2010) Vaccination with TAT-antigen fusion protein induces protective, CD8⁺ T cell-mediated immunity against Leishmania major. J Invest Dermatol 130:2602–2610PubMedCrossRef

54.

Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P (1987) Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 166:1654–1667PubMedCrossRef

55.

Larsen CP, Steinman RM, Witmer-Pack M, Hankins DF, Morris PJ, Austyn JM (1990) Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 172:1483PubMedCrossRef

56.

Kripke ML, Munn CG, Jeevan A, Tang JM, Bucana CJ (1990) Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J Immunol 145:2833–2838PubMed

57.

Sato N, Ahuja SK, Quinones M, Kostecki V, Reddick RL, Melby PC, Kuziel WA, Ahuja SS (2000) CC chemokine receptor (CCR) 2 is required for Langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation. J Exp Med 192:205–218PubMedCrossRef

58.

Moll H, Fuchs H, Blank C, Röllinghoff M (1993) Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immunol 23:1595–1601PubMedCrossRef

59.

Reiner SL, Zheng S, Wang Z-E, Stowring L, Locksley RM (1994) Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4⁺ T cells during initiation of infection. J Exp Med 179:447–456PubMedCrossRef

60.

Carrera L, Gazzinelli RT, Badolato R, Hieny S, Müller W, Kühn R, Sacks DL (1996) Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 183:515–526PubMedCrossRef

61.

Ramachandra L, Boom WH, Harding CV (2008) Class II MHC antigen processing in phagosomes. Methods Mol Biol 445:353–377PubMedCrossRef

62.

Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, Belkaid Y, Sacks DL (2005) Antigen requirements for efficient priming of CD8⁺ T cells by Leishmania major-infected dendritic cells. Infect Immun 73:6620–6628PubMedCrossRef

63.

Miller JF, Kurts C, Allison J, Kosaka H, Carbone F, Heath WR (1998) Induction of peripheral CD8⁺ T-cell tolerance by cross-presentation of self antigens. Immunol Rev 165:267–277PubMedCrossRef

64.

den Haan JM, Lehar SM, Bevan MJ (2000) CD8⁺ but not CD8⁻ dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192:1685–1696CrossRef

65.

Kloetzel PM (2001) Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179–187PubMedCrossRef

66.

Kalergis AM, Ravetch JV (2002) Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 195:1653–1659PubMedCrossRef

67.

Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C, Houde M, Desjardins M, Sher A, Sacks D (2006) Leishmania antigens are presented to CD8⁺ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol 177:3525–3533PubMed

68.

*Brosch S, Tenzer S, Akkad N, Lorenz B, Schild H, von Stebut E (2012) Priming of Leishmania-reactive CD8⁺ T cells in vivo does not require LMP7-containing immunoproteasomes. J Invest Dermatol 132:1302–1305PubMedCrossRef

69.

Brewig N, Kissenpfennig A, Malissen B, Veit A, Bickert T, Fleischer B, Mostböck S, Ritter U (2009) Priming of CD8⁺ and CD4⁺ T cells in experimental leishmaniasis is initiated by different dendritic cell subtypes. J Immunol 182:774–783PubMed

70.

Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG (1993) Resolution of cutaneous leishmaniasis: interleukin-12 initiates a protective T helper type 1 immune response. J Exp Med 177:1797–1802PubMedCrossRef

71.

Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK (1993) Recombinant interleukin-12 cures mice infected with Leishmania major. J Exp Med 177:1505–1509PubMedCrossRef

72.

Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, Gately MK, Louis JA, Alber G (1996) Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26:1553–1559PubMedCrossRef

73.

Heinzel FP, Rerko RM, Ahmed F, Pearlman E (1995) Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 155:730–739PubMed

74.

*von Stebut E (2011) Research in practice: different dendritic cell types in skin with various functions—important implications for intradermal vaccines. J Dtsch Dermatol Ges 9:506–509

75.

Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C, Vicari A, O’Garra A, Biron C, Briere F, Trinchieri G (2001) Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2:1144–1150PubMedCrossRef

76.

Wu L, Dakic A (2004) Development of dendritic cell system. Cell Mol Immunol 1:112–118PubMed

77.

Wilson NS, El Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath WR, Shortman K, Villadangos JA (2003) Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102:2187–2194PubMedCrossRef

78.

Leon B, Lopez-Bravo M, Ardavin C (2007) Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26:519–531PubMedCrossRef

79.

Valladeau J, Clair-Moninot V, Dezutter-Dambuyant C, Pin JJ, Kissenpfennig A, Mattei MG, Ait-Yahia S, Bates EE, Malissen B, Koch F, Fossiez F, Romani N, Lebecque S, Saeland S (2002) Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol 168:782–792PubMed

80.

Takahara K, Omatsu Y, Yashima Y, Maeda Y, Tanaka S, Iyoda T, Clausen BE, Matsubara K, Letterio J, Steinman RM, Matsuda Y, Inaba K (2002) Identification and expression of mouse Langerin (CD207) in dendritic cells. Int Immunol 14:433–444PubMedCrossRef

81.

Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N, Tripp CH, Douillard P, Leserman L, Kaiserlian D, Saeland S, Davoust J, Malissen B (2005) Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22:643–654PubMedCrossRef

82.

Douillard P, Stoitzner P, Tripp CH, Clair-Moninot V, Ait-Yahia S, McLellan AD, Eggert A, Romani N, Saeland S (2005) Mouse lymphoid tissue contains distinct subsets of langerin/CD207 dendritic cells, only one of which represents epidermal-derived Langerhans cells. J Invest Dermatol 125:983–994PubMedCrossRef

83.

Poulin LF, Henri S, de Bovis B, Devilard E, Kissenpfennig A, Malissen B (2007) The dermis contains langerin⁺ dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med 204:3119–3131PubMedCrossRef

84.

Ginhoux F, Collin MP, Bogunovic M, Abel M, Leboeuf M, Helft J, Ochando J, Kissenpfennig A, Malissen B, Grisotto M, Snoeck H, Randolph G, Merad M (2007) Blood-derived dermal langerin⁺ dendritic cells survey the skin in the steady state. J Exp Med 204:3133–3146PubMedCrossRef

85.

Bursch LS, Wang L, Igyarto B, Kissenpfennig A, Malissen B, Kaplan DH, Hogquist KA (2007) Identification of a novel population of Langerin⁺ dendritic cells. J Exp Med 204:3147–3156PubMedCrossRef

86.

Henri S, Poulin LF, Tamoutounour S, Ardouin L, Guilliams M, de Bovis B, Devilard E, Viret C, Azukizawa H, Kissenpfennig A, Malissen B (2010) CD207⁺ CD103⁺ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J Exp Med 207:189–206PubMedCrossRef

87.

Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, Clausen BE (2005) Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 169:569–576PubMedCrossRef

88.

Noordegraaf M, Flacher V, Stoitzner P, Clausen BE (2010) Functional redundancy of Langerhans cells and Langerin⁺ dermal dendritic cells in contact hypersensitivity. J Invest Dermatol 130:2752–2759PubMedCrossRef

89.

*Kautz-Neu K, Noordegraaf M, Dinges S, Bennett CL, John D, Clausen BE, von Stebut E (2011) Langerhans cells are negative regulators of the anti-Leishmania response. J Exp Med 208:885–891PubMedCrossRef

90.

*von Stebut E, Ehrchen JM, Belkaid Y, Kostka SL, Molle K, Knop J, Sunderkotter C, Udey MC (2003) Interleukin 1α promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 198:191–199CrossRef

91.

Filippi C, Hugues S, Cazareth J, Julia V, Glaichenhaus N, Ugolini S (2003) CD4⁺ T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. J Exp Med 198:201–209PubMedCrossRef

92.

*Zahn S, Wirtz S, Birkenbach M, Blumberg RS, Neurath MF, von Stebut E (2005) Impaired Th1 responses in mice deficient in Epstein-Barr virus-induced gene 3 and challenged with physiological doses of Leishmania major. Eur J Immunol 35:1106–1112PubMedCrossRef

Title: Dendritic cells in Leishmania major infections: mechanisms of parasite uptake, cell activation and evidence for physiological relevance
Authors: Kordula Kautz-Neu
Kirsten Schwonberg
Michael R. Fischer
Anja I. Schermann
Esther von Stebut
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Medical Microbiology and Immunology / Issue 4/2012
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-012-0261-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Dendritic cells in Leishmania major infections: mechanisms of parasite uptake, cell activation and evidence for physiological relevance

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Mechanisms of invasion and persistence of infectious agents

Malaria and human red blood cells

Live or let die: manipulation of cellular suicide programs by murine cytomegalovirus

Census of cytosolic aminopeptidase activity reveals two novel cytosolic aminopeptidases

Murine cytomegalovirus immune evasion proteins operative in the MHC class I pathway of antigen processing and presentation: state of knowledge, revisions, and questions

Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page